By Brent MacDonald
Upfront payment of $75 Million, up to $2.6 Billion in milestone payments from collaboration, plus tiered royalties. By Brent MacDonald – Partner at Rising Tide Aspect Biosystems (herewith “Aspect”) seeks to revolutionize drug development, personalized medicine, and regenerative medicine by becoming the global leader in 3D human tissue technology. Its disruptive 3D bioprinting platform technology […]
By Brent MacDonald
3x faster than Chrome. Better protection from Google and Big Tech By Brent MacDonald – Principal at Rising Tide A sea of advertisements, hackers, and echo chambers is the Internet. Big Tech informs us what is true and what is not true while making enormous profits off of user data. Brave is fighting back! Individuals’ online […]
By Brent MacDonald
Dear Esteemed Partners and Friends: We are pleased to welcome you to our quarterly newsletter, which summarizes how Rising Tide links money with the chance to generate value and forge a better future. We take immense pride in the success and steady growth of our portfolio and, importantly, the confidence our Limited Partners have in […]
Streamlined communication and surveillance in the VHF, UHF, L, S, C, X, Ku, Ka, and optical bands By Brent MacDonald – Principal at Rising Tide Global satellite data transmission services and products are offered by RBC Signals, a cutting-edge company. Using a global network of both company- and partner-owned equipment, it provides secure space communication solutions in […]
By Brent MacDonald
By Brent MacDonald – Partner at Rising Tide Castle stops account-related attacks, including automated account takeover, manual phishing, and registration misuse. Hundreds of millions of user accounts are protected by Castle Nowadays, a password is required for practically all of the things we do online or on our phones. The majority of individuals reuse passwords, […]
By Brent MacDonald
By Brent MacDonald – Partner at Rising Tide Some of the most difficult problems in the world could be solved through synthetic biology, but to go forward more quickly, gene synthesis needs to be improved. Evonetix completes an oversubscribed $24 million financing round, extending its total Series B funding to over $54 million. By creating a […]